131052-40-9

Basic information

• Product Name: 5-tert-Butoxycarbonylamino-pyridine-2-carboxylic acid methyl ester
• Synonyms: 5-tert-Butoxycarbonylamino-pyridine-2-carboxylic acid methyl ester;Methyl 5-(tert-butoxycarbonylamino)picolinate
• CAS NO: 131052-40-9
• Molecular Formula: C₁₂H₁₆N₂O₄
• Molecular Weight: 252.27
• Mol File: 131052-40-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: 145-146 °C
• Boiling Point: 341.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.203±0.06 g/cm3(Predicted)
• PKA: 12.36±0.70(Predicted)
• CAS DataBase Reference: 5-tert-Butoxycarbonylamino-pyridine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-Butoxycarbonylamino-pyridine-2-carboxylic acid methyl ester(131052-40-9)
• EPA Substance Registry System: 5-tert-Butoxycarbonylamino-pyridine-2-carboxylic acid methyl ester(131052-40-9)

Safety Data

• Hazardous Substances Data: 131052-40-9(Hazardous Substances Data)

Upstream product

• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67515-76-8 methyl 5-amino-2-pyridinecarboxylate 
• 17874-76-9 6-(methoxycarbonyl)nicotinic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 323578-38-7 tert-butyl N-[6-(hydroxymethyl)pyridin-3-yl]carbamate 
• 873651-92-4 (5-aminopyridin-2-yl)methanol 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

BICYCLIC INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.